Benzinga | Jul 1, 2021 06:40AM EDT

Jazz Pharma's Rylaze Scores FDA Approval For Blood Cancer

* The FDA has approved Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in pediatric and adult patients.

* The approval covers the use of Rylaze as a component of a multi-agent chemotherapeutic regimen in patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase.

* The company expects Rylaze will be commercially available in mid-July.

* Price Action: JAZZ closed at $177.64 on Wednesday.